Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

suite2321

To: li3511 who wrote (48036)	12/10/2018 9:04:31 PM
From: rodneyh07	1 Recommendation Read Replies (1) of 63283

My friend who is friend with Rob told me some of the following: “Manufacturing audits occur frequently particularly with biological and antibody drug conjugates that involve complex methodology. Lack of drains and air pressure are very actionable and can be immediately addressed. The more concerning component is the data breach - hard to say from the warning letter if the issue is poor laboratory practice or a falsified effort to mislead. The company will have 90 days to address and reply. I wouldn’t panic - I know you’ve had a position in This stock for a while. These audits become more frequent in Phase III and as you approach commercial supply.” Yes there is a concern possible, but it has nothing to do with data... We r use to issue, but we have a great team running the show. This obviously is not our forte, so lesson learned. Rodney

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next